Cambridge’s Aveo Pharmaceuticals Inc. rose on its offering of 6.7 million shares for $7.50 each. The company said it expects to raise about $50 million before discounts and commissions. The offering is expected to close on Wednesday. Aveo helped develop an experimental cancer pill — Tivopath — that is currently under review by the Food and Drug Administration to treat advanced kidney cancer. The agency is expected to finish its review by July.
Globe wires January 19, 2013
Read it all, now.
Don't miss any of your favorite stories again. Read the stories that matter to you as much as you want, whenever you want when you subscribe to BostonGlobe.com.
Get full access today for just 99¢